HCC1428 is an epithelial cell that was isolated from the mammary gland of a 49-year old, White female patient with adenocarcinoma, TNM stage IV, grade 4. The cell was deposited by AF Gazdar and AK Virmani and can be used in cancer research.

2020年8月8日 · Silencing of ESR1-CCDC170 in the fusion-positive cell line, HCC1428, downregulates HER2/HER3, represses pSRC/pAKT, and improves endocrine sensitivity. More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib …

2012年4月4日 · Part of: ICBP43 breast cancer cell line panel. Part of: MD Anderson Cell Lines Project. Population: Caucasian. Doubling time: 88.48 hours (JWGray panel). Microsatellite instability: Stable (MSS) (Sanger). Omics: Array-based CGH. Omics: CNV analysis.

HCC1428 was resistant to cisplatin, and depletion of BRCA2 or FANCA sensitized HCC1428 to cisplatin (mean s.e.m., n = 3).

Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 1 of 2: Normalized growth rate inhibition values.

来自同一患者的EBV转化的淋巴母细胞样细胞系 [HCC1428 BL]可作为ATCC CRL-2328获得。 FHIT基因的纯合缺失保留在淋巴母细胞系中。 HCC1428是从一名49岁的患有腺癌的白人女性患者的乳腺中分离的上皮细胞，TNM IV期，4级。 该细胞由AF Gazdar和AK Virmani保存，可用于癌症研究。 Q：为什么我看的文献里的细胞培养条件和你们官网的培养条件不一样呢？ A：部分细 …

Characteristics: Derived from parent cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed= 26116361). Derived from site: Metastatic; Pleural effusion; UBERON= UBERON_0000175.

Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.

2019年9月16日 · abeled stable pool in the designated cell type. This stable cell line expre. ses firefly luciferase and eGFP simultaneously. This cell line can be used in vitro for cancer cell line research or in vivo to es. ablish orthotopic or subcutaneous tumor models. Tumor gr.

The HCC1428 human breast adenocarcinoma (ER⁺/PR⁺/HER2⁻) xenograft model is used to evaluate therapeutic efficacy of investigational antineoplastic agent(s) in immune compromised mice.